Journal
EUROPEAN JOURNAL OF CANCER
Volume 42, Issue 10, Pages 1501-1506Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.03.011
Keywords
breast cancer; trastuzumab; HER-2 gene; chromosome 17 aneusomy; HER-2 gene signal number; IHC 2+; FISH
Categories
Ask authors/readers for more resources
Our aim was to determine the aneusomy level and the HER-2 gene copy numbers, by fluorescence in situ hybridization (FISH) and to analyze their impact on the amplification rate in breast carcinomas considered HER-2 weakly positive cases by immunohistochemistry. We evaluated 343 breast carcinomas using double colour FISH (LSI Her-2/neu gene and CEP 17). Monosomy and polysomy were demonstrated in 24.2% and 46.1% respectively and 101/343 (29.6%) of the specimens were amplified by FISH. A statistically significant difference was observed, when we compared the amplification percentage in polysomic and monosomic specimens (P < 0.0001) and, among polysomic specimens, when tumours were compared with HER-2 gene signals number per cell between 3 and 10 and > 10 respectively (P < 0.0001). Logistic regression analysis showed that HER-2 signals > 10 and polysomy absence were independently associated with amplification. Our results confirm that the majority of 2+ IHC cases express the HER-2 protein without gene amplification and highlight the effect of chromosome 17 aneusomy and the HER-2 gene copy number on amplification. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available